Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial
Martin Belkin, Nathalie Franchimont, Maria L. Naylor, H. Hartung et al.
Citations
1 citations
Journal
Multiple Sclerosis Journal
Topics
Multiple Sclerosis Research Studies
Field-Weighted Citation Impact (FWCI)
1.47
article
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial
Martin Belkin, Nathalie Franchimont, Maria L. Naylor, H. Hartung, Andrija Javor, Ian Tagge, Shibeshih Mitiku Belachew, Daniel P. Bradley, SD Newsome, Bing Zhu, Katherine Riester, Peter A. Calabresi, Maria Pia Sormani, E Bartholomé, Douglas Lorne Arnold, Robert T. Naismith, Jennifer Lyons, Aaron Deykin, Wenjie Cheng, Elizabeth Fisher, R M Fox, Martin Valis, Ludwig Kappos, Gavin Giovannoni
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Multiple Sclerosis JournalVol. 32(1)
Institutions
Montreal Neurological Institute and Hospital (CA), Biogen (United States) (US), Cleveland Clinic (US), Queen Mary University of London (GB), Washington University in St. Louis (US), Charles University (CZ), University Hospital of Basel (CH), Hospital Base (CL), Michigan Institute for Neurological Disorders (US), NeuroRx Research (Canada) (CA), Johns Hopkins Hospital (US), Heinrich Heine University Düsseldorf (DE), McGill University (CA), Palacký University Olomouc (CZ), University of Genoa (IT)